
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8304417/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
2	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. Arthritis Care and Research, 2022, 74, 1623-1630.	3.4	3
3	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.9	42
4	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
5	Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40 years of follow-up. Rheumatology, 2022, 62, 200-208.	1.9	4
6	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome. Frontiers in Immunology, 2022, 13, 842923.	4.8	0
7	Extent of vascular plaque predicts future cardiovascular events in patients with systemic lupus erythematosus. Rheumatology, 2022, 62, 225-233.	1.9	4
8	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	3.4	13
9	Flares in patients with systemic lupus erythematosus. Rheumatology, 2021, 60, 3262-3267.	1.9	5
10	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	3.4	22
11	Total plaque area and plaque echogenicity are novel measures of subclinical atherosclerosis in patients with systemic lupus erythematosus. Rheumatology, 2021, 60, 4185-4198.	1.9	3
12	Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. Scientific Reports, 2021, 11, 4542.	3.3	3
13	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology, 2021, 60, 4737-4747.	1.9	14
14	Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1446-1458.	2.4	26
15	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	1.6	3
16	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	5.6	7
17	Why Do Patients With Systemic Lupus Erythematosus Suffer Pain?. Journal of Rheumatology, 2021, 48, 1195-1197.	2.0	1
18	Antiphospholipid syndrome and pregnancy. British Journal of Midwifery, 2021, 29, 308-309.	0.4	0

#	Article	IF	CITATIONS
19	Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus. Expert Review of Clinical Immunology, 2021, 17, 957-967.	3.0	22
20	1704â€Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
21	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	2.7	97
22	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
23	Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology, 2020, 59, 524-533.	1.9	19
24	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	2.0	34
25	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	5.6	39
26	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Reviews, 2020, 39, 100610.	5.7	85
27	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. Rheumatology, 2020, 59, 146-152.	1.9	14
28	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	3.4	23
29	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	5.6	26
30	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	6.5	27
31	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.9	40
32	P118 Orthopaedic surgical interventions in a cohort of patients with hypermobility related disorders, compared with chronic pain syndrome patients in a tertiary referral centre. Rheumatology, 2020, 59, .	1.9	0
33	P170 Predictors of renal survival in a cohort of patients with lupus nephritis with more than 30 years of follow-up. Rheumatology, 2020, 59, .	1.9	0
34	P172 Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development. Rheumatology, 2020, 59, .	1.9	0
35	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus, 2020, 29, 1571-1593.	1.6	80
36	P59â€Predictors of renal survival in a cohort of patients with lupus nephritis with more than 30 years of follow-up. , 2020, , .		0

#	Article	IF	CITATIONS
37	P145â€Membranous and proliferative lupus nephritis – analysis of a nationwide multicentre cohort. , 2020, , .		0
38	P21â€Investigation of possible pathogenic autoantibodies in membranous lupus nephritis. , 2020, , .		0
39	P31â€Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development. , 2020, , .		Ο
40	P42â€Disease activity, impaired iron transport and failed sequestration: a novel mechanism for anaemia in systemic lupus erythematosus. , 2020, , .		0
41	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	3.4	9
42	Unusual presentations in patients with systemic lupus erythematosus: a result of disease activity or something else?. British Journal of Hospital Medicine (London, England: 2005), 2020, 81, 1-3.	0.5	0
43	Management of antiphospholipid syndrome. Clinical Rheumatology, 2020, 39, 2111-2114.	2.2	5
44	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	5.6	17
45	Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study. Scientific Reports, 2020, 10, 3102.	3.3	5
46	Outcomes of membranous and proliferative lupus nephritis – analysis of a single-centre cohort with more than 30 years of follow-up. Rheumatology, 2020, 59, 3314-3323.	1.9	9
47	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	3.4	70
48	E088 Antiphospholipase A2 receptor antibodies, a marker of idiopathic membranous nephropathy, are not present in membranous lupus nephritis. Rheumatology, 2019, 58, .	1.9	0
49	022 Both Domain I and PEGylated Domain I of Beta-2-Glycoprotein I (β2GPI) are capable of inhibiting IgA APS antibody binding. Rheumatology, 2019, 58, .	1.9	Ο
50	E024â $\in$ fInvariant natural killer T cells in RA and CVD. Rheumatology, 2019, 58, .	1.9	0
51	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	2.0	15
52	242 Baseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). Rheumatology, 2019, 58, .	1.9	0
53	Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. BMJ Open, 2019, 9, e028697.	1.9	15
54	Menorrhagia: an underappreciated problem in pre-menopausal women with systemic lupus erythematosus. Lupus, 2019, 28, 916-917.	1.6	3

#	Article	IF	CITATIONS
55	Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding inÂvitro: an effect enhanced by PEGylation. Lupus, 2019, 28, 893-897.	1.6	2
56	019 Modulation of monocyte autophagy as a therapeutic target in antiphospholipid syndrome. Rheumatology, 2019, 58, .	1.9	0
57	I099 Anti-phospholipid antibody syndrome. Rheumatology, 2019, 58, .	1.9	0
58	I059 Atherosclerosis in lupus: can early detection be achieved and acted upon?. Rheumatology, 2019, 58,	1.9	0
59	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	5.6	25
60	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	1.9	8
61	How to investigate: Very early inflammatory rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101454.	3.3	Ο
62	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.9	12
63	Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes. , 2019, , 355-365.		4
64	Antilipoprotein and Antiendothelial Cell Antibodies. , 2019, , 375-376.		0
65	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	5.6	55
66	Testing a support programme for opioid reduction for people with chronic non-malignant pain: the I-WOTCH randomised controlled trial protocol. BMJ Open, 2019, 9, e028937.	1.9	6
67	Red cell distribution width correlates with fatigue levels in a diverse group of patients with systemic lupus erythematosus irrespective of anaemia status. Clinical and Experimental Rheumatology, 2019, 37, 852-854.	0.8	3
68	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 393-396.	2.0	27
69	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	1.9	37
70	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	3.4	55
71	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology, 2018, 57, 470-479.	1.9	73
72	Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. Cell Death and Disease, 2018, 8, e2549-e2549.	6.3	17

#	Article	IF	CITATIONS
73	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. Arthritis Care and Research, 2018, 70, 98-103.	3.4	26
74	Managing conventional cardiovascular risk factors in the lupus clinic – what can we achieve?. Lupus, 2018, 27, 172-173.	1.6	0
75	Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Clinical Reviews in Allergy and Immunology, 2018, 55, 352-367.	6.5	75
76	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	3.4	21
77	Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a cohort analysis of the COPERS trial. BMJ Open, 2018, 8, e019491.	1.9	44
78	i048 Adult SLE: survivors from childhood onset. Rheumatology, 2018, 57, .	1.9	0
79	133 Functional iron deficiency: a potential novel mechanism for fatigue in systemic lupus erythematosus. Rheumatology, 2018, 57, .	1.9	0
80	141 Evaluating the prevalence of heavy menstrual bleeding (menorrhagia) in patients with systemic lupus erythematosus. Rheumatology, 2018, 57, .	1.9	0
81	CS-07â€Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
82	132 Going viral in rheumatology: a rapid, cost-effective method of obtaining patient opinion about mechanistic research in SLE and APSA. Rheumatology, 2018, 57, .	1.9	2
83	138 Disease trends and phenotypes among different age groups: a study in lupus. Rheumatology, 2018, 57,	1.9	0
84	252 Examining the modulatory effects of anti-serine protease antibodies upon factor Xa, thrombin and complement interactions. Rheumatology, 2018, 57, .	1.9	0
85	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. Frontiers in Immunology, 2018, 9, 2413.	4.8	14
86	Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome. Rheumatology Advances in Practice, 2018, 2, rky003.	0.7	11
87	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. Frontiers in Immunology, 2018, 9, 2244.	4.8	11
88	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. Journal of Autoimmunity, 2018, 93, 114-123.	6.5	24
89	140 Evaluating the prevalence of iron deficiency and anaemia in systemic lupus erythematosus. Rheumatology, 2018, 57, .	1.9	1
90	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268

#	Article	IF	CITATIONS
91	A critical analysis of the tools to evaluate neuropsychiatric lupus. Lupus, 2017, 26, 504-509.	1.6	17
92	316. INCREASED RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO HAVE ASYMPTOMATIC PLAQUE ON VASCULAR ULTRASOUND: A 5 YEAR FOLLOW-UP STUDY. Rheumatology, 2017, 56, .	1.9	0
93	Atherosclerosis in systemic lupus erythematosus. Best Practice and Research in Clinical Rheumatology, 2017, 31, 364-372.	3.3	45
94	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome. Scientific Reports, 2017, 7, 10788.	3.3	7
95	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. Rheumatology, 2017, 56, 1041-1043.	1.9	2
96	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	3.5	1
97	IO9. TREAT TO TARGET IN LUPUS. Rheumatology, 2017, 56, .	1.9	0
98	O34. ANTI-PHOSPHOLIPID ANTIBODIES DIFFERENTIALLY REGULATE THE EXPRESSION AND ACTIVITY OF THE LYSOSOMAL PROTEASES WITH EFFECTS UPON MONOCYTE AUTOPHAGY. Rheumatology, 2017, 56, .	1.9	0
99	239. PEGYLATED DOMAIN I OF BETA-2-GLYCOPROTEIN I PREVENTS THROMBOSIS IN A MOUSE MODEL. Rheumatology, 2017, 56, .	1.9	0
100	Oxidation of $\hat{I}^22$ -glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. PLoS ONE, 2017, 12, e0186513.	2.5	8
101	064. FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatology, 2017, 56, .	1.9	0
102	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
103	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. , 2017, , 77-116.		3
104	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. , 2017, , 171-187.		3
105	Measuring IgA Anti-β2-Glycoprotein I and IgC/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. PLoS ONE, 2016, 11, e0156407.	2.5	66
106	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	5.6	40
107	Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. Science Immunology, 2016, 1, .	11.9	44
108	Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. Rheumatology, 2016, 55, 1243-1250.	1.9	28

#	Article	IF	CITATIONS
109	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 2016, 68, 1505-1513.	3.4	45
110	The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis. Molecular Immunology, 2016, 75, 161-167.	2.2	14
111	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	1.9	370
112	Novel Three-Day, Community-Based, Nonpharmacological Group Intervention for Chronic Musculoskeletal Pain (COPERS): A Randomised Clinical Trial. PLoS Medicine, 2016, 13, e1002040.	8.4	45
113	Rheumatoid Arthritis and Incidence of Twelve Initial Presentations of Cardiovascular Disease: A Population Record-Linkage Cohort Study in England. PLoS ONE, 2016, 11, e0151245.	2.5	50
114	Improving the self-management of chronic pain: COping with persistent Pain, Effectiveness Research in Self-management (COPERS). Programme Grants for Applied Research, 2016, 4, 1-440.	1.0	21
115	New therapeutic avenues in SLE. Best Practice and Research in Clinical Rheumatology, 2015, 29, 794-809.	3.3	11
116	Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. BMC Biotechnology, 2015, 15, 104.	3.3	8
117	Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with â€~seronegative' antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2015, 74, 317-319.	0.9	42
118	lgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. Arthritis Research and Therapy, 2015, 17, 26.	3.5	23
119	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Arthritis Research and Therapy, 2015, 17, 47.	3.5	16
120	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	5.6	98
121	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of Â2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology, 2015, 54, 722-727.	1.9	67
122	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.9	70
123	Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmunity Reviews, 2015, 14, 153-159.	5.8	106
124	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.9	391
125	Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. Lupus Science and Medicine, 2014, 1, e000013.	2.7	5
126	PEGylated drugs in rheumatology–why develop them and do they work?. Rheumatology, 2014, 53, 391-396.	1.9	30

#	Article	IF	CITATIONS
127	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. Arthritis Research and Therapy, 2014, 16, R48.	3.5	4
128	Efficacy of an out-patient pain management programme for people with joint hypermobility syndrome. Clinical Rheumatology, 2014, 33, 1665-1669.	2.2	18
129	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Annals of the Rheumatic Diseases, 2014, 73, 138-142.	0.9	115
130	Taking a closer look at biologic therapy for SLE. Nature Reviews Rheumatology, 2014, 10, 71-72.	8.0	10
131	Fibromyalgia. BMJ, The, 2014, 348, g1224-g1224.	6.0	84
132	25â€Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort. Arthritis Care and Research, 2014, 66, 1167-1176.	3.4	49
133	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmunity Reviews, 2014, 13, 917-930.	5.8	224
134	Cancer risk in systemic lupus: An updated international multi-centre cohort study. Journal of Autoimmunity, 2013, 42, 130-135.	6.5	249
135	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84
136	The Research that Time Forgot. British Journal of Hospital Medicine (London, England: 2005), 2013, 74, 702-703.	0.5	0
137	Effectiveness and cost-effectiveness of a novel, group self-management course for adults with chronic musculoskeletal pain: study protocol for a multicentre, randomised controlled trial (COPERS). BMJ Open, 2013, 3, e002492.	1.9	15
138	Pain management for chronic musculoskeletal conditions: the development of an evidence-based and theory-informed pain self-management course. BMJ Open, 2013, 3, e003534.	1.9	23
139	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2013, 72, 1308-1314.	0.9	78
140	Imaging Assessment of Cardiovascular Disease in Systemic Lupus Erythematosus. Clinical and Developmental Immunology, 2012, 2012, 1-7.	3.3	19
141	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.9	143
142	Effective Delivery Styles and Content for Self-management Interventions for Chronic Musculoskeletal Pain. Clinical Journal of Pain, 2012, 28, 344-354.	1.9	113
143	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
144	Review: Can we identify how programmes aimed at promoting selfâ€management in musculoskeletal pain work and who benefits? A systematic review of subâ€group analysis within RCTs. European Journal of Pain, 2011, 15, 775.e1-11.	2.8	75

#	Article	IF	CITATIONS
145	Evaluating the conformation of recombinant domain I of β2-glycoprotein I and its interaction with human monoclonal antibodies. Molecular Immunology, 2011, 49, 56-63.	2.2	16
146	Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β <sub>2</sub> â€glycoprotein I. Arthritis and Rheumatism, 2011, 63, 2774-2782.	6.7	96
147	Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. Arthritis and Rheumatism, 2011, 63, 3512-3521.	6.7	15
148	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology, 2011, 50, 982-988.	1.9	155
149	Antibodies to apolipoprotein Aâ€I, highâ€density lipoprotein, and Câ€reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2010, 62, 845-854.	6.7	100
150	Numerical scoring for the BILAG-2004 index. Rheumatology, 2010, 49, 1665-1669.	1.9	111
151	Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways. Journal of Immunology, 2010, 184, 6622-6628.	0.8	67
152	Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. Journal of Rheumatology, 2010, 37, 322-329.	2.0	83
153	Thrombin Binding Predicts the Effects of Sequence Changes in a Human Monoclonal Antiphospholipid Antibody on Its In Vivo Biologic Actions. Journal of Immunology, 2009, 182, 4836-4843.	0.8	19
154	Numerical scoring for the Classic BILAG index. Rheumatology, 2009, 48, 1548-1552.	1.9	35
155	Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology, 2009, 48, 673-675.	1.9	204
156	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology, 2009, 48, 691-695.	1.9	90
157	Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Research and Therapy, 2009, 11, R154.	3.5	107
158	Systemic Lupus Erythematosus. New England Journal of Medicine, 2008, 358, 929-939.	27.0	1,548
159	Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. Rheumatology, 2008, 48, 573-575.	1.9	23
160	Structure-Function Relationships in Anti-DNA and Anti-Phospholipid Antibodies and their Relevance to the Pathogenesis of Disease. Current Rheumatology Reviews, 2008, 4, 2-11.	0.8	2
161	Origin and structure of autoantibodies and antigens in autoimmune rheumatic diseases. Lupus, 2008, 17, 232-235.	1.6	7
162	Do high-sensitivity C-reactive protein levels help predict risk of cardiovascular disease in patients with osteoarthritis?. Nature Clinical Practice Rheumatology, 2008, 4, 122-123.	3.2	0

#	Article	IF	CITATIONS
163	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human β2-glycoprotein I: Mutation studies including residues R39 to R43. Arthritis and Rheumatism, 2007, 56, 280-290.	6.7	134
164	Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. Arthritis and Rheumatism, 2007, 56, 2392-2401.	6.7	12
165	British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 4113-4119.	6.7	96
166	Systemic lupus erythematosus. Orphanet Journal of Rare Diseases, 2006, 1, 6.	2.7	173
167	Lessons from Sequence Analysis of Monoclonal Antiphospholipid Antibodies. , 2006, , 470-491.		2
168	A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnology, 2006, 6, 8.	3.3	33
169	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case–control study. Arthritis and Rheumatism, 2006, 55, 892-899.	6.7	95
170	Structure and function of autoantibodies and their role in autoimmune rheumatic diseases. Expert Review of Clinical Immunology, 2006, 2, 225-236.	3.0	1
171	Arginine Residues Are Important in Determining the Binding of Human Monoclonal Antiphospholipid Antibodies to Clinically Relevant Antigens. Journal of Immunology, 2006, 177, 1729-1736.	0.8	30
172	"It struck me that they didn't understand pain― The specialist pain clinic experience of patients with chronic musculoskeletal pain. Arthritis and Rheumatism, 2005, 53, 691-696.	6.7	56
173	Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. Arthritis Research and Therapy, 2005, 7, R971.	3.5	14
174	The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. Arthritis Research, 2005, 7, R47.	2.0	22
175	Is ?-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?. Arthritis and Rheumatism, 2004, 50, 866-870.	6.7	90
176	Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. Molecular Immunology, 2004, 40, 745-758.	2.2	15
177	Important determinants of self-efficacy in patients with chronic musculoskeletal pain. Journal of Rheumatology, 2004, 31, 1187-92.	2.0	16
178	A systematic analysis of sequences of human antiphospholipid and anti–β2-glycoprotein I antibodies: The importance of somatic mutations and certain sequence motifs. Seminars in Arthritis and Rheumatism, 2003, 32, 246-265.	3.4	36
179	How do antiphospholipid antibodies bind ?2-glycoprotein I?. Arthritis and Rheumatism, 2003, 48, 2111-2121.	6.7	58
180	Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. Molecular Immunology, 2003, 40, 49-60.	2.2	25

#	Article	IF	CITATIONS
181	Molecular expression systems for anti-DNA antibodies—1. Lupus, 2002, 11, 824-832.	1.6	7
182	Systematic analysis of sequences of anti-DNA antibodies—relevance to theories of origin and pathogenicity. Lupus, 2002, 11, 807-823.	1.6	44
183	Anti-DNA antibodies—structure and function. Lupus, 2002, 11, 776-779.	1.6	6
184	Anti-DNA antibodies - overview of assays and clinical correlations. Lupus, 2002, 11, 770-773.	1.6	33
185	Molecular and genetic characterizations of five pathogenic and two non-pathogenic monoclonal antiphospholipid antibodies. Molecular Immunology, 2002, 39, 299-311.	2.2	26
186	The importance of somatic mutations in the Vλ gene 2a2 in human monoclonal anti-DNA antibodies. Journal of Molecular Biology, 2001, 307, 149-160.	4.2	29
187	Molecular Cloning and Expression of the Fabs of Human Autoantibodies in Escherichia coli. Journal of Biological Chemistry, 2000, 275, 35129-35136.	3.4	19
188	Structure–function analysis and the molecular origins of anti-DNA antibodies in systemic lupus erythematosus. Expert Reviews in Molecular Medicine, 1999, 1, 1-28.	3.9	7
189	Immunoglobulin variable region sequences of humanmonoclonal anti-DNA, antibodies. Seminars in Arthritis and Rheumatism, 1998, 28, 141-154.	3.4	36
190	The role of in vitro expression systems in the investigation of antibodies to DNA. Seminars in Arthritis and Rheumatism, 1998, 28, 130-139.	3.4	3
191	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	1.9	0